Sun Pharmaceutical Industries Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SUNPHARMA BSE: 524715

₹1816.60

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #1 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited (this stock)	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹448,865 Cr

EV / EBITDA

70.1x

EV / Sales

21.48x

Market cap / Sales

20.85x

Earnings yield

0.68%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 5,881 Cr, up 3.1% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 1,115 Cr, up 48.0% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	5,741	1,486	1,115	₹4.6000
March 31, 2026	4,924	849	609	₹2.5000
Dec. 31, 2025	5,688	1,097	705	₹2.9000
Sept. 30, 2025	4,548	672	564	₹2.4000
June 30, 2025	5,602	1,185	754	₹3.1000
March 31, 2025	7,186	2,612	2,000	₹8.3000
Dec. 31, 2024	6,192	1,265	1,181	₹4.9000
Sept. 30, 2024	5,128	896	863	₹3.6000
June 30, 2024	4,498	258	238	₹1.0000
March 31, 2024	5,639	1,402	868	₹3.6000
Dec. 31, 2023	5,074	751	721	₹3.0000
Sept. 30, 2023	5,096	907	889	₹3.7000
June 30, 2023	4,466	390	381	₹1.6000

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	5,881	4,987	5,868	4,621	5,706	7,318	6,260	5,214	4,581	5,758	5,151	5,203	4,630
Operating revenue	5,741	4,924	5,688	4,548	5,602	7,186	6,192	5,128	4,498	5,639	5,074	5,096	4,466
Other income	140	63	180	73	104	132	68	86	83	119	77	107	164
Operating expenses	3,777	3,595	3,929	3,365	3,711	4,196	4,488	3,789	3,737	3,746	3,715	3,710	3,517
Operating profit	1,964	1,329	1,759	1,184	1,891	2,989	1,703	1,339	761	1,894	1,359	1,386	949
Operating profit margin	34.2%	27.0%	30.9%	26.0%	33.8%	41.6%	27.5%	26.1%	16.9%	33.6%	26.8%	27.2%	21.2%
Depreciation	308	326	339	336	299	292	291	286	370	393	400	393	415
Interest	278	217	244	248	223	217	216	244	216	218	215	194	158
Exceptional items, gain / (loss)	-32	—	-259	—	-288	—	—	—	—	—	-70	—	-149
Profit before tax	1,486	849	1,097	672	1,185	2,612	1,265	896	258	1,402	751	907	390
Tax	371	240	392	108	431	612	84	32	20	534	30	18	9
Net profit	1,115	609	705	564	754	2,000	1,181	863	238	868	721	889	381
EPS	4.60	2.50	2.90	2.40	3.10	8.30	4.90	3.60	1.00	3.60	3.00	3.70	1.60
Net profit (TTM)	2,994	2,632	4,024	4,499	4,798	4,283	3,150	2,690	2,715	2,858	970	735	1,060
EPS (TTM)	12.40	10.90	16.70	18.70	19.90	17.80	13.10	11.20	11.30	11.90	4.00	3.00	4.40

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	20,755	3,794	2,623
March 31, 2025	23,003	5,031	4,283
March 31, 2024	20,275	3,450	2,858
March 31, 2023	20,812	1,741	1,691

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	0.1%	10.3%	21,174^†	23,373^†	20,741^†	21,091^†	16,194^†	12,953^†	10,992^†	9,083^†	8,274^†
Operating revenue	-0.1%	10.1%	20,755	23,003	20,275	20,812	15,247^†	12,803^†	9,720^†	7,955^†	7,760^†
Other income	—	—	419^†	369^†	466^†	279^†	948^†	150^†	1,271^†	1,128^†	514^†
Operating expenses	—	—	14,599^†	16,211^†	14,688^†	14,339^†	12,095^†	9,867^†	8,421^†	7,837^†	7,442^†
Operating profit	-1.7%	16.0%	6,155^†	6,793^†	5,588^†	6,473^†	3,152^†	2,936^†	1,299^†	118^†	318^†
Operating profit margin	—	—	29.7%^†	29.5%^†	27.6%^†	31.1%^†	20.7%^†	22.9%^†	13.4%^†	1.5%^†	4.1%^†
Depreciation	—	—	1,300^†	1,238^†	1,601^†	1,601^†	1,194^†	587^†	530^†	431^†	419^†
Interest	—	—	933^†	893^†	784^†	472^†	386^†	257^†	541^†	388^†	224^†
Exceptional items, gain / (loss)	—	—	-546^†	0^†	-219^†	-2,938^†	-1,655^†	-90^†	-1,214^†	-950^†	0^†
Profit before tax	29.6%	12.0%	3,794	5,031	3,450	1,741	864^†	2,153^†	285^†	-524^†	-32^†
Tax	—	—	1,171^†	748^†	591^†	50^†	407^†	13^†	-97^†	-27^†	3^†
Net profit	15.8%	4.2%	2,623	4,283	2,858	1,691	458^†	2,140^†	382^†	-497^†	-35^†
EPS	15.9%	4.1%	10.90^†	17.80^†	11.90^†	7.00^†	1.85^†	8.92^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Operating margin	29.7%^†	29.5%^†	27.6%^†	31.1%^†	20.7%^†	22.9%^†	13.4%^†	1.5%^†	4.1%^†
EBIT margin	22.8%^†	25.8%^†	20.9%^†	10.6%^†	8.2%^†	18.8%^†	8.5%^†	-1.7%^†	2.5%^†
PBT margin	18.3%	21.9%	17.0%	8.4%	5.7%^†	16.8%^†	2.9%^†	-6.6%^†	-0.4%^†
Net margin	12.6%	18.6%	14.1%	8.1%	3.0%^†	16.7%^†	3.9%^†	-6.3%^†	-0.5%^†
Interest coverage	5.07x^†	6.63x^†	5.40x^†	4.69x^†	3.24x^†	9.38x^†	1.53x^†	-0.35x^†	0.85x^†
Dividend payout	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—
Current ratio	2.56x	1.03x	—	—	—	—	—	—	—
Quick ratio	1.90x	0.82x	—	—	—	—	—	—	—
Debt to equity	0.60x	0.45x	—	—	—	—	—	—	—
Return on equity	11.7%	17.6%	—	—	—	—	—	—	—
Return on assets	6.1%	9.9%	—	—	—	—	—	—	—
Return on capital employed	12.9%^†	23.6%^†	—	—	—	—	—	—	—
Asset turnover	0.48x	0.53x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	6,501	-1,381	-5,230	1,543	4,958
March 31, 2025	4,199	-210	-3,831	711	3,488
March 31, 2024	-292	-263	474	749	-1,042
March 31, 2023	507	-705	169	962	-455
March 31, 2022	7,636	-2,702	-4,871	850	6,786

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	43,060	22,371	22,131	0	13,420	16,679	6,503	418	5,145	4,302
March 31, 2025	43,273	24,340	24,100	10,954	0	18,722	18,149	492	4,345	3,787
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.